<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03702309</url>
  </required_header>
  <id_info>
    <org_study_id>LIBERATE</org_study_id>
    <nct_id>NCT03702309</nct_id>
  </id_info>
  <brief_title>Liquid Biopsy Evaluation and Repository Development at Princess Margaret</brief_title>
  <acronym>LIBERATE</acronym>
  <official_title>Liquid Biopsy Evaluation and Repository Development at Princess Margaret</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this protocol is to develop an institution-wide liquid biopsy protocol that&#xD;
      will establish a common process for collecting blood and corresponding archived tumor&#xD;
      specimens for future research studies at the University Health Network's Princess Margaret&#xD;
      Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA)&#xD;
      and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic&#xD;
      and prognostic information before cancer diagnosis, during cancer treatment, and at disease&#xD;
      progression. Cancer research scientists and clinicians at the Princess Margaret are&#xD;
      interested in incorporating the collection of peripheral blood samples (&quot;liquid biopsies&quot;)&#xD;
      into research protocols as a means of non-invasively assessing tumor progression and response&#xD;
      to treatment at multiple time points during a patient's course of disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2017</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Collection and annotation of biospecimens</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>Facilitate and streamline the collection, banking, and annotation of biospecimens (especially liquid biopsy specimens and optionally corresponding archived tumor specimens) for research studies across the University Health Network institution</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electronic Consenting</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>Implement an electronic informed consent process for clinical research at the Princess Margaret Cancer Centre</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlative Studies Questionnaire</measure>
    <time_frame>Through study completion, up to 5 years</time_frame>
    <description>Collect observational/epidemiological data using a Correlative Studies Questionnaire for clinical annotation of specimens and future research use. Data collected involves demographics such as family history, medical history, smoking history, and lifestyle.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Lymphoma</condition>
  <condition>Leukemia</condition>
  <condition>Mutation</condition>
  <condition>Lynch Syndrome</condition>
  <condition>Cowden Syndrome</condition>
  <condition>BRCA1 Mutation</condition>
  <condition>BRCA2 Mutation</condition>
  <condition>Uterine Cancer</condition>
  <condition>Myeloma</condition>
  <condition>Kidney Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Meningioma</condition>
  <arm_group>
    <arm_group_label>LIBERATE</arm_group_label>
    <description>Patients with either histological confirmation of a solid tumor or hematological malignancy, or patients identified as high-risk for cancer (based on identified aberration in cancer predisposition gene or on hormonal and/or family history without known aberration).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood samples collected serially for DNA extraction Archived tissue samples&#xD;
      collected for DNA extraction&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with solid tumors or hematological malignancy and patients identified as high-risk&#xD;
        for cancer.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with either histological confirmation of a solid tumor or hematological&#xD;
             malignancy, OR patients identified as high-risk for cancer (based on identified&#xD;
             aberration in cancer predisposition gene or on hormonal and/or family history without&#xD;
             known aberration).&#xD;
&#xD;
          2. Patient must be â‰¥ 18 years old.&#xD;
&#xD;
          3. All patients must have signed and dated an informed consent form for this LIBERATE&#xD;
             study.&#xD;
&#xD;
          4. If patients are being co-consented for a separate primary research study listed in&#xD;
             Appendix I, they must fulfill the eligibility criteria for that separate primary&#xD;
             research study. If there is a discrepancy in the eligibility criteria between&#xD;
             protocols, the separate primary research study's criteria take precedence.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lillian Siu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Celeste Yu, MSc</last_name>
    <phone>416-946-4501</phone>
    <phone_ext>5281</phone_ext>
    <email>Celeste.Yu@uhn.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lillian Siu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.cancergenomicsprogram.ca/</url>
    <description>Princess Margaret Cancer Genomics Program</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High Risk</keyword>
  <keyword>Liquid Biopsy</keyword>
  <keyword>Circulating Tumor DNA</keyword>
  <keyword>Blood</keyword>
  <keyword>Molecular Profiling</keyword>
  <keyword>Next Generation Sequencing</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Hematological</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningioma</mesh_term>
    <mesh_term>Colorectal Neoplasms, Hereditary Nonpolyposis</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Hamartoma Syndrome, Multiple</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Potential to share de-identified study data (including genetic data) with approved research collaborators.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

